Updated:
Spruce Biosciences
Spruce Biosciences was founded in 2014 and listed on Nasdaq in 2020 via a traditional IPO.
Spruce Biosciences
Spruce Biosciences was founded in 2014 and listed on Nasdaq in 2020 via a traditional IPO. The company did not emerge from a family office or wealth corpus; it was built in the standard biotech venture mold, backed by life-science investors such as Abingworth, Omega Funds, and RiverVest Venture Partners. From inception, its pipeline concentrated on a single molecule, tildacerfont, a CRF1 receptor antagonist. The investment thesis operates entirely within clinical-stage biotechnology — no diversification across sectors, no lending, no real assets. Capital has funded a Phase 2b/3 program in classic congenital adrenal hyperplasia (CAH) and a smaller exploratory trial in polycystic ovary syndrome. By mid-2024 the firm had completed enrollment in its pivotal CAHmelia-203 study in adult patients and a separate CAHptain-205 study in pediatric patients. Its geographic focus is the United States, with all trial sites and regulatory efforts centered on FDA approval. No marketed product exists; revenue has been zero throughout the company's life. As a public micro-cap biotech, the firm's resources are a function of its cash runway rather than a permanent capital base. As of the first quarter of 2024, the company reported approximately $31 million in cash and equivalents, which it projected would fund operations into mid-2025 — a classic pre-catalyst runway that hinges entirely on a single Phase 3 data readout. The subsequent readout in Q3 2024 failed to meet its primary endpoint, triggering a sharp restructuring. The firm's total headcount was roughly 30 to 40 employees before that workforce reduction. Spruce occupies the most undiversified structure in the biotech asset class: the single-asset, pre-revenue orphan-drug company. Succession and governance track standard public-company norms, but the operational reality is binary — a positive trial validates years of burn; a negative one eliminates the enterprise. That tight coupling between a single clinical dataset and the firm's continuation is the defining structural constraint for any allocator assessing it.
General information
Firm type
Asset Manager
Year founded
2014
AUM
Undisclosed
Location
Region
North America
Country
United States
City
South San Francisco
Corporate office
South San Francisco, CA, United States
Principals
Javier Szwarcberg
Chief Executive Officer
Richard King
Chief Executive Officer (former)
Sector focus
Frequently asked questions
Who runs investment and capital-allocation decisions at Spruce Biosciences?
Javier Szwarcberg, MD, MPH, has served as Chief Executive Officer since September 2020 and previously as Chief Medical Officer. He sets the clinical and capital strategy alongside the board, which includes representatives from lead venture backers Abingworth, Omega Funds, and RiverVest. The firm does not have a CIO or separate investment committee — resource allocation is a function of the CEO and CFO managing a single clinical program's budget.
What is the company's sole clinical asset and how does it drive the firm's value?
The entire enterprise value is tied to tildacerfont, an oral CRF1 receptor antagonist studied in classic congenital adrenal hyperplasia. Because Spruce has no marketed products or secondary pipeline assets of material scale, the drug's Phase 3 efficacy data acts as the binary toggle for the firm's survival — positive results could open a path to an NDA filing and potential acquisition or partnership; negative results, as seen in September 2024, force immediate cash-conservation measures.
How does Spruce Biosciences fund its operations?
The firm raised capital through venture equity from life-science specialists like Abingworth, Omega Funds, and RiverVest Venture Partners, followed by a $99 million Nasdaq IPO in October 2020. Post-IPO, it has relied on its cash balance and periodic at-the-market equity offerings. It carries no disclosed debt facility of scale and generates no recurring revenue, making its equity value purely a function of clinical catalysts and cash runway.
Is Spruce Biosciences a single-family office or a venture fund?
Neither. Spruce is a clinical-stage public biotechnology company trading on Nasdaq. It bears no structural resemblance to a family office or a partnership-style venture fund — it is a traditional Delaware-incorporated corporation with a professional management team, a public board, and a single drug program.
What is the firm's geographic focus?
All disclosed clinical trial sites for its lead program are in the United States, and the company targets FDA approval as its primary regulatory pathway. There is no disclosed operational footprint, partnership, or clinical-trial activity in Europe or Asia as of the latest SEC filings.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: